Long-Term Quality of Life Among Patients Undergoing Endoscopic Pituitary Gland Surgery
<b>Introduction/Objectives:</b> The endoscopic approach to skull base lesions is widely regarded as less invasive and associated with reduced morbidity, offering favorable outcomes, particularly in terms of short-term quality of life (QOL). However, to date, long-term assessments of both nasal function and tumor-related QOL remain limited. To evaluate patients' long-term nasal- and tumor-related QOL after endoscopic endonasal resection of pituitary tumors and to detect predictors for poor postoperative QOL. Study Design: This study was a prospective cohort study. <b>Methods:</b> All patients with pituitary adenomas who underwent trans-sphenoidal surgery at Tel Aviv Sourasky Medical Center between 2014 and 2021 were recruited. Recruited patients completed the Anterior Skull Base Disease-Specific QOL (ASBS-Q) questionnaire and the Sinonasal Outcome Test 22 (SNOT-22) questionnaire before surgery and 1, 2, and 3-5 years after surgery. Clinical data were collected and analyzed. <b>Results:</b> The study included 43 patients (18 women). No significant decrease was observed in tumor-related quality of life (QOL) scores, measured by ASBS-Q and SNOT-22, throughout the 5-year follow-up period. SNOT-22 score differences from the preoperative baseline at years 1, 3, and 5 were 0.81 [-4.84-6.58], 3.35 [-4.32-11.02], and 3.73 [-2.22-9.68], respectively, with no statistically significant changes. ASBS-Q scores similarly showed no significant changes over time. Subgroup analyses revealed that tumor characteristics (secreting vs. non-secreting, size), surgical factors (intraoperative cerebrospinal fluid leak, gross tumor resection, use of nasoseptal flap), and endocrine remission did not significantly impact QOL (<i>p</i> > 0.05 for all variables). <b>Conclusions:</b> Our study demonstrated that patients who underwent endoscopic pituitary lesion resection maintained high nasal- and tumor-related quality of life over a 5-year follow-up period. However, given the limitations of our study, further multi-center studies with larger patient populations are warranted to validate these results.
Authors
- Narin N. Carmel Neiderman (ORCID: https://orcid.org/0000-0003-0628-1942)
- Tomer Ziv‐Baran (ORCID: https://orcid.org/0000-0002-2589-8473)
- Stuart S. Kaufman (ORCID: https://orcid.org/0000-0002-5308-4565)
- Avraham Abergel (ORCID: https://orcid.org/0000-0002-9360-8888)
- Anat Wengier (ORCID: https://orcid.org/0000-0002-2282-8170)
- Ran Bilaus
Institutions
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3390/jcm13216371
- Citations
- 6
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15